Home › Triple-Negative Breast Cancer › NCT06586047

Breast Cancer PSMA PET

Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT

Who can join

Ages 18 to 90 · Women

Inclusion Criteria:

* Female \>= 18 years of age
* Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
* Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.

Exclusion Criteria:

* Patients with known active other malignancy.
* Unable to tolerate PET/CT procedure.
* Pregnant or breastfeeding.
* Patients with any medical condition that might compromise the safety of subject during PET acquisitions.

About the study

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

What is being tested

• PET imaging (diagnostic test)

Sponsor: Ahmad Shariftabrizi · Participants: 30 · Started: Aug 29, 2024

Contact the study team

• Ahmad Shariftabrizi, M.D. · Phone: 319-887-4942
• Elina Shrestha · Phone: 319 335 0114

Official record on ClinicalTrials.gov — NCT06586047

Locations in the U.S.

Conditions

• Triple-Negative Breast Cancer
• Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.